Related Experiment Video
Updated: Jul 8, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
COQ2-Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review
Yuqi Yue1, Fei Zhao1, Qiuxia Chen1
1Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Background:
Primary coenzyme Q10 (CoQ10) deficiency (PCOQ10D) is an autosomal recessive mitochondrial disorder caused by pathogenic variants in genes involved in the CoQ10 biosynthetic pathway, including PDSS2, COQ2, COQ6, and COQ8B/ADCK4. Among these, pathogenic variants in the COQ2 gene impair oxidative phosphorylation and mitochondrial biogenesis in podocytes, often leading to encephalopathy and nephropathy.
Methods:
Clinical data were collected from a pediatric patient with proteinuria caused by COQ2 gene variants, who was admitted to the Children's Hospital Affiliated to Nanjing Medical University in June 2025. Relevant examinations were completed, and whole-exome sequencing (WES) was performed to screen for potential genetic variants in the patient's genomic DNA. Pathogenicity assessment of the identified variants was conducted in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines and online bioinformatics tools. Additionally, a systematic literature review on COQ2-associated nephropathy was carried out in this study.
Results:
The patient initially presented with global developmental delay accompanied by neurological lesions and developed proteinuria at 6 months of age. Genetic testing revealed two pathogenic variants: c.368G>A, p.(Arg123His) and c.908A>G, p.(Tyr303Cys). After oral administration of high-dose CoQ10 (85 mg/kg/d) combined with enalapril maleate (0.80 mL/kg/d), the patient achieved complete remission of proteinuria and maintained stable renal function.
Conclusions:
PCOQ10D exhibits marked phenotypic heterogeneity, characterized by variations in age of onset, organ involvement, and clinical severity, as well as significant interindividual differences in treatment responses to CoQ10 supplementation. This case expands the phenotypic spectrum of the disease. Moreover, the therapeutic outcomes suggest that all diagnosed patients require long-term supplementation with adequate doses of CoQ10, which is of great significance for delaying disease progression.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
